Expression of prostaglandin- and vitamin D-metabolising enzymes in benign and malignant breast cells

Anticancer Research

Volumn 32, Issue 1 PART 2, 2012, Pages 367-372

  Thill, Marc ^a   Hoellen, Friederike ^a   Becker, Steffi ^a   Dittmer, Christine ^a,c   Fischer, Dorothea ^a   Kümmel, Sherko ^c   Salehin, Darius ^b   Friedrich, Michael ^b   Köster, Frank ^a   Diedrich, Klaus ^a   Cordes', Tim ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Helios Hospital Krefeld   (Germany)

^c Hospital Essen Mitte   (Germany)

Author keywords

Breast cancer; Cyclooxygenase 2; Prostaglandin metabolism; VDR; Vitamin D metabolism

Indexed keywords

CYCLOOXYGENASE 2; OXYGENASE; PROSTAGLANDIN;

BREAST CANCER; CANCER CELL CULTURE; CARCINOGENESIS; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; VITAMIN D METABOLISM; WESTERN BLOTTING;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; BLOTTING, WESTERN; BREAST; BREAST NEOPLASMS; CELLS, CULTURED; CYCLOOXYGENASE 2; DINOPROSTONE; FEMALE; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; NEOPLASM INVASIVENESS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CALCITRIOL; RNA, MESSENGER; STEROID HYDROXYLASES;

EID: 84856015561     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. 2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 101(2): 591-596, 2004.
2. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB and De Marzo AM: Cyclooxygenases in cancer: progress and perspective. Cancer Lett 215: 1-20,2004. (Pubitemid 39221453)
3. Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H and Isola J: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62: 632-635,2002. (Pubitemid 34126931)
4. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, Loar A, Rodabough RJ, White E and McTiernan A; Women's Health Initiative: Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 63: 6096-6101, 2003. (Pubitemid 37187516)
5. Taketo MM: Cyclooxygenase-2 inhibitors in tumorigenesis (part I): J Natl Cancer Inst 90: 1529-1536, 1998.
6. +-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 26: 65-72, 2005.
7. Wolf I, O'Kelly J, Rubinek T, Tong M, Nguyen A, Lin BT, Tai HH, Karlan BY and Koeffler HP: 15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 66(75): 7818-7823, 2006. (Pubitemid 44289243)
8. Salhab M, Singh-Ranger G, Mokbel R, Jouhra F, Jiang WG and Mokbel K: Cyclooxygenase-2 mRNA expression correlates with aromatase expression in human breast cancer. J Surg Oncol 96(5): 424-428, 2007. (Pubitemid 47519449)
9. James SY, Mercer E, Brady M, Binderup L and Colston KW: EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro. Br J Pharmacol 125(5): 953-962,1998. (Pubitemid 28495355)
10. 3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc Natl Acad Sci USA 80(1): 201-204, 1983.
11. Janowsky EC, Lester GE, Weinberg CR, Millikan RC, Schildkraut JM, Garrett PA and Hulka BS: Association between low levels of 1,25-dihydroxyvitamin D and breast cancer risk. Public Health Nutr 2: 283-291, 1999. (Pubitemid 29446591)
12. Goodwin PJ, Ennis M, Pritchard KI, Koo J and Hood N: Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 27(23): 3757-3763, 2009.
13. Frazier AL, Ryan CT, Rockett H, Willett WC and Colditz GA: Adolescent diet and risk of breast cancer. Breast Cancer Res 5: R59-64, 2003.
14. Frazier AL, Li L, Cho E, Willett WC and Colditz GA: Adolescent diet and risk of breast cancer. Cancer Causes Control 15: 73-82, 2004. (Pubitemid 38339974)
15. McCullough ML, Rodriguez C, Diver WR, Feigelson HS, Stevens VL.Thun MJ and Calle EE: Dairy, calcium, and vitamin D intake and postmenopausal breast cancer risk in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 14: 2898-2904, 2005. (Pubitemid 43068822)
16. Rossi M, McLaughlin JK, Lagiou P, Bosetti C, Talamini R, Lipworth L, Giacosa A, Montella M, Franceschi S, Negri E and La Vecchia C: Vitamin D intake and breast cancer risk: a case-control study in Italy. Ann Oncol 20(2): 374-378, 2009.
17. Dusso AS, Brown AJ and Slatopolsky E: Vitamin D. Am J Physiol Renal Physiol 289(1): F8-28, 2005.
18. Townsend K, Evans KN, Campbell MJ, Colston KW, Adams JS and Hewison M: Biological actions of extra-renal 25-hydroxyvitamin D-1 alpha-hydroxylase and implications for chemoprevention and treatment. J Steroid Biochem Mol Biol 97(1-2): 103-109, 2005. (Pubitemid 41546219)
19. Thill M, Fischer D, Becker S, Cordes T, Dittmer C, Diedrich K, Salehin D and Friedrich M: Prostaglandin metabolizing enzymes in correlation with vitamin D receptor in benign and malignant breast cell lines. Anticancer Res 29(9): 3619-3625, 2009.
20. 3 in breast cancer. Anticancer Res 30(5): 1673-1679,2010.
21. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA and Jothy S: Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55(12): 2556-2559, 1995.
22. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR, Nucleic Acids Res 29(9): e45, 2001.
23. Half E,Tang XM, Gwyn K, Sahin A, Wathen K and Sinicrope FA: Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62: 1676-1681, 2002. (Pubitemid 34408488)
24. Denkert C, Winzer KJ, Müller BM, Weichen W, Pest S, Köbel M, Kristiansen G, Reles A, Siegert A, Guski H and Hauptmann S: Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 97(12): 2978-2987, 2003. (Pubitemid 36676251)
25. Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ and Mukherjee P: Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2(11): 632-642, 2004. (Pubitemid 39557666)
26. Basu GD, Pathangey LB, Tinder TL, Gendler SJ and Mukherjee P: Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res 7(4): R422-435, 2005.
27. Celis JE, Gromov P, Cabezón T, Moreira JM, Friis E, Jirström K, Llombart-Bosch A, Timmermans-Wielenga V, Rank F and Gromova I: 15-Prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma. Mol Cell Proteomics 7(10): 1795-809, 2008.
28. Watson J and Chuah SY: Technique for the primary culture of human breast cancer cells and measurement of their prostaglandin secretion. Clin Sci (Lond) 83(3): 347-352, 1992.
29. 2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators. Br J Cancer 72(6): 1412-1419,1995.
30. Kemmis CM, Salvador SM, Smith KM and Welsh J: Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3. J Nutr 136: 887-892, 2006.
31. Buras RR, Schumaker LM, Davoodi F, Brenner RV, Shabahang M, Nauta RJ and Evans SR: Vitamin D receptors in breast cancer cells. Breast Cancer Res Treat 31: 191-202, 1994. (Pubitemid 24323461)
32. 3 1 alpha-hydroxylase splice variants in breast cell lines MCF-7 and MCF-10. Cancer Genomics Proteomics 4(4): 295-300, 2007.
33. Cordes T, Diesing D, Becker S, Fischer D, Diedrich K and Friedrich M: Expression of splice variants of 1alpha-hydroxylase in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 103(3-5): 326-329, 2007. (Pubitemid 46401325)
34. Hiller M, Huse K, Platzer M and Backofen R: Non-EST based prediction of exon skipping and intron retention events using . Pfam information. Nucleic Acids Res 33(17): 5611-5621, 2005.
35. Ren S, Nguyen L, Wu S, Encinas C, Adams JS and Hewison M: Alternative splicing of vitamin D-24-hydroxylase: a novel mechanism for the regulation of extrarenal 1,25-dihydroxyvitamin D synthesis. J Biol Chem 280(21): 20604-2061, 2005.
36. Cordes T, Fischer D, Thill M, Becker S, Friedrich M and Salehin D: Vitamin D-1alpha-hydroxylase and vitamin D-24-hydroxylase in benign and malign breast tissue. Eur J Gynaecol Oncol 31(2): 151-155,2010.
37. Rozic JG, Chakraborty C and Lala PK: Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 93:497-506,2001. (Pubitemid 32701408)
38. Takkouche B, Regueira-Méndez C and Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 100(20): 1439-1447, 2008.
39. Ma Y, Trump DL and Johnson CS: Vitamin D in combination cancer treatment. J Cancer 15(1): 101-107, 2010.
40. Krishnan AV and Feldman D: Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. Endocr Relat Cancer 17(1): R19-38, 2010.
41. Scher HI, Jia X, Chi K, de Wit R, Berry WR, Albers P, Henick B, Waterhouse D, Ruether DJ, Rosen PJ, Meluch AA, Nordquist LT, Venner PM, Heidenreich A, Chu L and Heller G: Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 29(16): 2191-2198, 2011.